Aptorum Group Limited (NASDAQ:APM) Sees Large Drop in Short Interest

Posted by Lauren Steadman on Jul 16th, 2026

Aptorum Group Limited (NASDAQ:APM – Get Free Report) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 62,491 shares, a drop of 38.5% from the June 15th total of 101,658 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily volume of 42,111 shares, the days-to-cover ratio is presently 1.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Aptorum Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Stock Report on APM

Aptorum Group Stock Up 0.4%

Shares of Aptorum Group stock opened at $0.82 on Thursday. The firm’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $0.89. Aptorum Group has a 12 month low of $0.65 and a 12 month high of $4.47.

About Aptorum Group

(Get Free Report)

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.